Key result
Recent pharmacotherapy advances including SGLT2 inhibitors and sacubitril-valsartan rapidly reshape the HFrEF treatment landscape.
Why the study?
Although updated guidelines for HFrEF and acute decompensation have improved outcomes, ongoing efforts remain focused on examining the limitations of current treatments and assessing the potential impact of emerging therapies.
The review summarizes the rapidly evolving treatment landscape for HFrEF and acute decompensated heart failure, highlighting recent advances in pharmacotherapy.
INTRODUCTION: Updated guidelines for heart failure with reduced ejection fraction (HFrEF) and acute decompensation have improved outcomes, but ongoing efforts are focused on uncovering new evidence and developing novel therapies. This review examines the limitations of current treatments and the potential impact of emerging therapies. AREAS COVERED: A literature search focused on studies investigating drugs for HFrEF. We review recent clinical trials and emerging therapies to assess evidence strength, explore guideline updates, and identify strategies to optimize patient outcomes. EXPERT OPINION: The HFrEF treatment landscape is rapidly evolving, with advances in therapies like sodium/glucose cotransporter inhibitors and sacubitril-valsartan. Though managing acute decompensated heart failure remains challenging, recent trials suggest improvements in diuretic strategies and anti-inflammatory treatments. Ongoing research is essential for validating these therapies and incorporating them into standard practice.
No takes yet. Share an insight, caveat, or question.
Ismail et al. (2024) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Pharmacotherapy (including SGLT2 inhibitors and sacubitril-valsartan) was evaluated. Recent advances in pharmacotherapy for heart failure with reduced ejection fraction, including SGLT2 inhibitors and sacubitril-valsartan, are rapidly evolving the treatment landscape.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: